Overview
- The Supreme Court, which issued an administrative stay Monday through May 11, restored telehealth and mail dispensing of mifepristone and told Louisiana to respond by Thursday.
- A Fifth Circuit panel on Friday blocked the FDA's 2023 policy and reinstated a nationwide in-person pickup rule for the drug.
- Drugmakers Danco Laboratories and GenBioPro sought emergency relief, and the stay gives the justices time to consider their requests.
- Providers that paused teleprescribing or shifted to misoprostol-only protocols over the weekend say the brief reprieve eases disruption but leaves patients bracing for another change.
- Mifepristone, approved in 2000 and used with misoprostol for most U.S. abortions, is at the center of Louisiana's 2025 suit claiming mail access thwarts its ban, while the FDA maintains the drug is safe.